Ophthalmic Consultants of Boston
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1969-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.drraizman.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:3
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Not Applicable
1 (20.0%)Phase 4
1 (20.0%)YAG Vitreolysis for Floaters
Not Applicable
Completed
- Conditions
- FloatersWeiss RingPosterior Vitreous Detachment
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 52
- Registration Number
- NCT02897583
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
Phase 1
Completed
- Conditions
- Central Retinal Vein OcclusionProliferative Diabetic Retinopathy
- Interventions
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 24
- Registration Number
- NCT01724554
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
Phase 1
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 10
- Registration Number
- NCT00491166
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2010-01-08
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 30
- Registration Number
- NCT00395551
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
Phase 4
- Conditions
- Eye InfectionInfection
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2006-07-04
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 40
- Registration Number
- NCT00347828
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
News
No news found